

Press Release

30 May 2022

Clarify Pharma PLC

("Clarify Pharma" or "the Company")

Result of Annual General Meeting

Clarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed.

For further information please contact:

Clarify Pharma	
Jon Bixby Executive Chairman	via Tancredi +44 207 887 7633
First Sentinel	
Corporate Adviser Brian Stockbridge	+44 7876 888 011
Tennyson Securities	
Corporate Broker Peter Krens	+44 207 186 9030
Tancredi Intelligent Communication	
Media Relations Catrina Daly Emma Hodges Salamander Davoudi clarifypharma@tancredigroup.com	+44 7727 153 868 +44 7861 995 628 +44 7957 549 906

About Clarify Pharma PLC:

Listed on the Aquis Stock Exchange in London, Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing. The Company's Directors have an established track record,

experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation.
www.clarifypharma.com